Hong Kong Pharma Digital Technology (NASDAQ:HKPD) Stock Price Down 8.3% – Time to Sell?

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) traded down 8.3% on Tuesday . The stock traded as low as $0.4539 and last traded at $0.5340. 48,985 shares changed hands during mid-day trading, a decline of 86% from the average session volume of 342,883 shares. The stock had previously closed at $0.5825.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d)” rating on shares of Hong Kong Pharma Digital Technology in a report on Friday, May 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Hong Kong Pharma Digital Technology Price Performance

The company has a quick ratio of 2.73, a current ratio of 2.93 and a debt-to-equity ratio of 0.28. The firm has a fifty day simple moving average of $0.62 and a two-hundred day simple moving average of $0.77.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last released its earnings results on Wednesday, March 18th. The company reported $0.01 EPS for the quarter. The firm had revenue of $3.57 million for the quarter.

Institutional Investors Weigh In On Hong Kong Pharma Digital Technology

A hedge fund recently bought a new stake in Hong Kong Pharma Digital Technology stock. StoneX Group Inc. purchased a new stake in Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 43,284 shares of the company’s stock, valued at approximately $36,000. StoneX Group Inc. owned 0.39% of Hong Kong Pharma Digital Technology at the end of the most recent quarter.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.